A rare characteristic prokaryotic drug substance production platform in China, equipped with independent production lines of 500L and 2000L scales. This platform adopts E. coli and yeast expression systems, suitable for flexible production of nanobodies, recombinant proteins, microecological fermentation products, peptides and enzyme preparations.

Novel Multi-process Downstream Platform for Biopharmaceutical Fermentation (Invention Patent): It fully covers four expression modes, including intracellular soluble expression, inclusion body expression, periplasmic expression and extracellular secretory expression. It has mature experience in the R&D and commercial production of GLP‑1 analogues (such as semaglutide).

The platform is equipped with one independent microbial seed bank workshop and two independent animal cell seed bank workshops, all complying with GMP management requirements. The microbial seed bank workshop is fitted with a 0.5 m² freeze dryer for lyophilized powder preparation. The whole process is validated by APS to ensure no microbial contamination during preparation.